The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. The market’s growth is driven by factors such as the increasing R&D activities for the development of therapeutic mAbs. Furthermore, supportive government initiatives are further driving the overall market growth. The production of therapeutic antibodies has gained a rampant demand and is a vital factor projected to fuel the market growth over the forecast period.
Etesevimab and Bamlanivimab are monoclonal antibodies used specifically against the SARS-CoV-2 spike protein. Bamlanivimab and Etesevimab when administered in combination, can effectively treat patients with mild Covid-19. The National Institutes of Health (NIH) COVID-19 Treatment rules recommend that REGEN-COV™ usage and is approved by the FDA. Some of the other FDA-approved monoclonal antibodies include Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn), Dupixent® (dupilumab), REGEN-COVTM (casirivimab with imdevimab), Libtayo® (cemiplimab-rwlc), Kevzara® (sarilumab), Praluent® (alirocumab), Evkeeza™ (evinacumab-dgnb).
Browse Full Report With Table Of Content @ https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Monoclonal Antibodies Market Report Highlights
• In vivo technology is affordable than in vitro production techniques. The in vivo production technique is preferred for the high concentration of mAbs obtained through this method
• Therapeutic mAbs has found a widespread application in cancer treatment and the increasing occurrence of cancer including including brain tumor, non-small cell lung, breast, colorectal, ovarian, gastric, Hodgkin’s lymphoma, and melanoma is contributing to the expantion of the mAbs vertical
• North America dominated the market in 2015 due to the presence of a robust healthcare infrastructure, ample government funding, and technological advancements
Ask for Sample Pages @ https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market/request/rs1
Monoclonal Antibodies Market Segmentation
Grand View Research has segmented the monoclonal antibodies market by source type, production, indication, end-use, and region:
Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 – 2024)
• Murine
• Chimeric
• Humanized
• Human
Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 – 2024)
• In Vivo
• In Vitro
Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 – 2024)
• Cancer
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Microbial Diseases
• Others
Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 – 2024)
• Hospitals
• Research Institutes
• Others
Monoclonal Antibodies Regional Outlook (Market Revenue in USD Billion, 2013 – 2024)
• North America
• The U.S.
• Canada
• Europe
• Germany
• The U.K.
• Asia Pacific
• China
• India
• Japan
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• South Africa
List of Key Players of Monoclonal Antibodies Market
• Novartis AG, Pfizer, Inc.
• GlaxoSmithKline plc
• Amgen, Inc.
• Merck & Co., Inc.
• Daiichi Sankyo Company, Ltd.
• Abbott
• AstraZeneca
• Eli Lilly
Speak to Analyst @ https://www.grandviewresearch.com/inquiry/989/ibb
About Grand View Research
Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market